3Celermajer DS, Sorensen KE, Gooch NM, et al. Noninvasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis [ J ]. Lancet, 1992,340 : 1111-1115
4Flaker GC, Warnica JW, Sacks FM, et al. Pravastatin prevents clinical events in revascularized patiemts with average cholesterol levels[ J]. J Am Coll Cardiol, 1999,34 : 106-112
5Sack FM, Pfeffer MA, Moye L A ,et al. The effect of pravastatin on coronary events in patient with average cholesterol levels[J]. N Engl J Med,1996,335 :1001-1009
6Amtz HR,Wunderlich W,Schnitzer L,et al. The decisive importance of choleaterol lowering therapy for coronary lesions and clinical course immediately after an acute coronary event: short and long term results of a controlled stuty [ J ]. Circulation, 1998 (Suppl) : 1-45,222
7Silva EP, Fonseca FA, Ihara SS, et, al. Early benefits of pravastatin to experimentally induced atherosclerosis [ J ]. J Cardiovasc Pharmacol,2002,39 :389-395
8Stein JH, Carlsson CM, Papcke-Benson K, et al. The effects of lipid-lowering and antioxidant vitamine therapies on flow- mediated vasodilation of the brachial artery in older adults with hypercholesterolemia [ J ]. J Am Coll Cardiol, 2001,38 : 1806-1813
2Anon. ASHP Guidelines on Pharmaeist-eondu-eted Patient Education and Counseling[J]. Am J Health Syst Pharm, 1997, 54 (4) : 431-432.
3Pedersen CA, Schneider PJ, Santell JP, et al. ASHP National Survey of Pharmacy Practice in Acute Care Settings Monitoring, Patient Education, and Wellness- 2000[J]. AmJ Health Syst Pharm, 2000, 57 ( 23 ) : 2171-2172.
4Roter DL, Hall JA, Merisca R, et al. Effectiveness of Intcrventionsto Improve Patient Compliance: a Meta- analysis[J]. Med Care, 1998, 36 (8) : 1138-1139.
